Trade Celldex Therapeutics Inc - CLDX CFD

Trading Conditions

• Type: CFD
• Spread: 0.14
• Long position overnight funding adjustment: -0.02235%
• Short position overnight funding adjustment: 0.00012%
• Overnight funding adjustment time: 22:00 (UTC)
• Currency: USD
• Min traded quantity: 0.1
• Margin: 50.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premium: 1%

Key Stats

• Prev. Close: 25.94
• Open: 25.52
• 1-Year Change: 8.5%
• Day's Range: 24.83 - 25.85

Celldex Therapeutics Company profile

About Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. The Company is using the technologies to develop targeted immunotherapeutics consisting of protein-based molecules, such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases. It operates in development, manufacturing of therapeutics. Company's CDX-0159, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity. Its CDX-1140, an agonist monoclonal antibody targeted to CD40, a key activator of immune response, being studied in a Phase II study. The Company's CDX-527, a bispecific antibody that uses active anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway, for which it initiated a Phase II study in advanced solid tumors.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Celldex Therapeutics, Inc. revenues decreased 37% to $4.7M. Net loss increased 18% to $70.5M. Revenues reflect Revenue Sales of Goods & Services decrease of 99% to $31K, Contracts and Grants decrease of 10% to $4.6M. Higher net loss reflects Research and Development increase of 20% to $48.8M (expense), General and Administrative increase of 29% to $16.1M (expense).

Equity composition

Common Stock $.001 Par, 4/11, 297M auth., 32,326,382 issd. Insiders & stakeholders own 0.40%. PO:5/91, 2Mshs. @ $6.50 by Allen & Co. Private Placement: 11/95, 2.6M shs. PO: 8/96, 5M shs. @ $2.1875 by Genesis Merchant Group. 03/08, 1-for-12 reverse stock split. 10/08, Name changed from AVANT Immunotherapeutics, Inc.